Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis

Abstract. Intermittent intraperitoneal antibiotic administration appears as a practical and economical therapeutic concept in continuous peritoneal dialysis (CPD)-related peritonitis, but the equivalence of this principle with standard continuous treatment awaits confirmation by prospective, randomi...

Full description

Saved in:
Bibliographic Details
Main Authors: Schaefer, Franz (Author) , Klaus, Günter (Author) , Müller-Wiefel, Dirk E. (Author) , Mehls, Otto (Author)
Corporate Author: Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS) (Author)
Format: Article (Journal)
Language:English
Published: January 1, 1999
In: Journal of the American Society of Nephrology
Year: 1999, Volume: 10, Issue: 1, Pages: 136-145
ISSN:1533-3450
Online Access:Verlag, lizenzpflichtig, Volltext: https://jasn.asnjournals.org/content/10/1/136
Get full text
Author Notes:Franz Schaefer, Günter Klaus, Dirk E. Müller-Wiefel, Otto Mehls, and The Mid-Europpean Pediatric Perotoneal Dialysis Study Group (MEPPS)

MARC

LEADER 00000caa a2200000 c 4500
001 1744699976
003 DE-627
005 20230428033111.0
007 cr uuu---uuuuu
008 210114s1999 xx |||||o 00| ||eng c
035 |a (DE-627)1744699976 
035 |a (DE-599)KXP1744699976 
035 |a (OCoLC)1341385224 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
110 2 |a Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS)  |e VerfasserIn  |0 (DE-588)1225074061  |0 (DE-627)1744699291  |4 aut 
245 1 0 |a Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis  |c Franz Schaefer, Günter Klaus, Dirk E. Müller-Wiefel, Otto Mehls, and The Mid-Europpean Pediatric Perotoneal Dialysis Study Group (MEPPS) 
264 1 |c January 1, 1999 
300 |a 10 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 14.01.2021 
520 |a Abstract. Intermittent intraperitoneal antibiotic administration appears as a practical and economical therapeutic concept in continuous peritoneal dialysis (CPD)-related peritonitis, but the equivalence of this principle with standard continuous treatment awaits confirmation by prospective, randomized clinical trials. This study evaluates the efficacy, safety, and clinical acceptance of an initial combination treatment including a glycopeptide (vancomycin or teicoplanin) and ceftazidime, each applied either intermittently or continuously, in a cohort of pediatric patients with CPD-related peritonitis. Patients randomized for continuous treatment received an intraperitoneal loading dose of glycopeptide and ceftazidime followed by maintenance doses added to each dialysate bag. In the intermittent treatment groups, the glycopeptide was administered in two loading doses 7 d apart, and ceftazidime during one dialysis cycle per day. Initial treatment response was evaluated after 60 h by the change in a Disease Severity Score and by the clinical decision to continue initial treatment. Of 152 patients observed for a total of 234 patient years, 90 patients developed 195 episodes of peritonitis (including 27 relapses within 4 wk after end of treatment). Dialysate cultures were positive in 83% of the episodes. In Gram-positive peritonitis (79% of culture-positive cases), the primary success (overall 95%) and relapse rates (21%) were not different between continuous and intermittent, or between vancomycin and teicoplanin treatment. Oversensitivity reactions occurred in three and ototoxicity in one vancomycin-treated patient, whereas no such side effects were observed with teicoplanin. Residual renal function declined during peritonitis episodes regardless of treatment modality. In Gram-negative peritonitis (18% of cases), intermittent ceftazidime treatment was less successful than continuous treatment according to clinical judgment (3 of 11 versus 10 of 14, P < 0.05), but not when rated by Disease Severity Score (8 of 11 versus 12 of 14). In conclusion, intermittent and continuous intraperitoneal treatment of CPD-related peritonitis with glycopeptides and ceftazidime is equally efficacious and safe when measured by objective clinical criteria. This contrasts with a strong tendency of clinicians to move from intermittent to continuous treatment in severe peritonitis. 
700 1 |a Schaefer, Franz  |d 1961-  |e VerfasserIn  |0 (DE-588)1023365383  |0 (DE-627)718365577  |0 (DE-576)366705598  |4 aut 
700 1 |a Klaus, Günter  |e VerfasserIn  |0 (DE-588)1106410408  |0 (DE-627)863131182  |0 (DE-576)474097021  |4 aut 
700 1 |a Müller-Wiefel, Dirk E.  |e VerfasserIn  |0 (DE-588)1027458661  |0 (DE-627)729155854  |0 (DE-576)37323161X  |4 aut 
700 1 |a Mehls, Otto  |e VerfasserIn  |0 (DE-588)1111580413  |0 (DE-627)865658137  |0 (DE-576)476191424  |4 aut 
773 0 8 |i Enthalten in  |a American Society of Nephrology  |t Journal of the American Society of Nephrology  |d Washington, DC : American Society of Nephrology, 1990  |g 10(1999), 1, Seite 136-145  |h Online-Ressource  |w (DE-627)324616481  |w (DE-600)2029124-3  |w (DE-576)094113769  |x 1533-3450  |7 nnas 
773 1 8 |g volume:10  |g year:1999  |g number:1  |g pages:136-145  |g extent:10  |a Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis 
856 4 0 |u https://jasn.asnjournals.org/content/10/1/136  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210114 
993 |a Article 
994 |a 1999 
998 |g 1111580413  |a Mehls, Otto  |m 1111580413:Mehls, Otto  |d 910000  |d 910500  |e 910000PM1111580413  |e 910500PM1111580413  |k 0/910000/  |k 1/910000/910500/  |p 4  |y j 
998 |g 1106410408  |a Klaus, Günter  |m 1106410408:Klaus, Günter  |d 50000  |e 50000PK1106410408  |k 0/50000/  |p 2 
998 |g 1023365383  |a Schaefer, Franz  |m 1023365383:Schaefer, Franz  |d 910000  |d 910500  |e 910000PS1023365383  |e 910500PS1023365383  |k 0/910000/  |k 1/910000/910500/  |p 1  |x j 
999 |a KXP-PPN1744699976  |e 3836471140 
BIB |a Y 
SER |a journal 
JSO |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1744699976","name":{"displayForm":["Franz Schaefer, Günter Klaus, Dirk E. Müller-Wiefel, Otto Mehls, and The Mid-Europpean Pediatric Perotoneal Dialysis Study Group (MEPPS)"]},"language":["eng"],"relHost":[{"title":[{"title":"Journal of the American Society of Nephrology","title_sort":"Journal of the American Society of Nephrology","subtitle":"JASN"}],"id":{"issn":["1533-3450"],"eki":["324616481"],"zdb":["2029124-3"]},"disp":"American Society of NephrologyJournal of the American Society of Nephrology","origin":[{"dateIssuedDisp":"1990-","publisherPlace":"Washington, DC ; [Erscheinungsort nicht ermittelbar]","dateIssuedKey":"1990","publisher":"American Society of Nephrology ; Ovid"}],"corporate":[{"display":"American Society of Nephrology","role":"aut"}],"note":["Gesehen am 19.08.24"],"titleAlt":[{"title":"JASN"}],"pubHistory":["1.1990 -"],"part":{"extent":"10","pages":"136-145","year":"1999","issue":"1","text":"10(1999), 1, Seite 136-145","volume":"10"},"physDesc":[{"extent":"Online-Ressource"}],"recId":"324616481","type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng"]}],"physDesc":[{"extent":"10 S."}],"id":{"eki":["1744699976"]},"corporate":[{"role":"aut","display":"Mid-European Pediatric Peritoneal Dialysis Study Group (MEPPS)"}],"origin":[{"dateIssuedKey":"1999","dateIssuedDisp":"January 1, 1999"}],"note":["Gesehen am 14.01.2021"],"person":[{"given":"Franz","display":"Schaefer, Franz","role":"aut","family":"Schaefer"},{"display":"Klaus, Günter","family":"Klaus","role":"aut","given":"Günter"},{"given":"Dirk E.","display":"Müller-Wiefel, Dirk E.","role":"aut","family":"Müller-Wiefel"},{"family":"Mehls","role":"aut","display":"Mehls, Otto","given":"Otto"}],"title":[{"title_sort":"Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis","title":"Intermittent versus continuous intraperitoneal glycopeptide/ceftazidime treatment in children with peritoneal dialysis-associated peritonitis"}]} 
SRT |a MIDEUROPEAINTERMITTE1199